

Identification and characterization of two consistent osteoarthritis subtypes by transcriptome and clinical data integration

Coutinho de Almeida, Rodrigo; Mahfouz, Ahmed; Mei, Hailiang; Houtman, Evelyn; den Hollander, Wouter; Soul, Jamie; Suchiman, Eka; Nelissen, Rob G.H.H.; Reinders, Marcel; More Authors

DOI

[10.1093/rheumatology/keaa391](https://doi.org/10.1093/rheumatology/keaa391)

Publication date

2021

Document Version

Final published version

Published in

Rheumatology (Oxford, England)

Citation (APA)

Coutinho de Almeida, R., Mahfouz, A., Mei, H., Houtman, E., den Hollander, W., Soul, J., Suchiman, E., Nelissen, R. G. H. H., Reinders, M., & More Authors (2021). Identification and characterization of two consistent osteoarthritis subtypes by transcriptome and clinical data integration. *Rheumatology (Oxford, England)*, 60(3), 1166-1175. <https://doi.org/10.1093/rheumatology/keaa391>

Important note

To cite this publication, please use the final published version (if applicable).
Please check the document version above.

Copyright

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Takedown policy

Please contact us and provide details if you believe this document breaches copyrights.
We will remove access to the work immediately and investigate your claim.

Original article

Identification and characterization of two consistent osteoarthritis subtypes by transcriptome and clinical data integration

Rodrigo Coutinho de Almeida ¹, Ahmed Mahfouz^{2,3}, Hailiang Mei⁴, Evelyn Houtman¹, Wouter den Hollander¹, Jamie Soul⁵, Eka Suchiman¹, Nico Lakenberg¹, Jennifer Meessen^{1,6}, Kasper Huetink⁶, Rob G. H. H. Nelissen⁶, Yolande F. M. Ramos¹, Marcel Reinders^{1,2,3} and Ingrid Meulenbelt¹

Abstract

Objective. To identify OA subtypes based on cartilage transcriptomic data in cartilage tissue and characterize their underlying pathophysiological processes and/or clinically relevant characteristics.

Methods. This study includes $n=66$ primary OA patients (41 knees and 25 hips), who underwent a joint replacement surgery, from which macroscopically unaffected (preserved, $n=56$) and lesioned ($n=45$) OA articular cartilage were collected [Research Arthritis and Articular Cartilage (RAAK) study]. Unsupervised hierarchical clustering analysis on preserved cartilage transcriptome followed by clinical data integration was performed. Protein–protein interaction (PPI) followed by pathway enrichment analysis were done for genes significant differentially expressed between subgroups with interactions in the PPI network.

Results. Analysis of preserved samples ($n=56$) resulted in two OA subtypes with $n=41$ (cluster A) and $n=15$ (cluster B) patients. The transcriptomic profile of cluster B cartilage, relative to cluster A (DE-AB genes) showed among others a pronounced upregulation of multiple genes involved in chemokine pathways. Nevertheless, upon investigating the OA pathophysiology in cluster B patients as reflected by differentially expressed genes between preserved and lesioned OA cartilage (DE-OA-B genes), the chemokine genes were significantly downregulated with OA pathophysiology. Upon integrating radiographic OA data, we showed that the OA phenotype among cluster B patients, relative to cluster A, may be characterized by higher joint space narrowing (JSN) scores and low osteophyte (OP) scores.

Conclusion. Based on whole-transcriptome profiling, we identified two robust OA subtypes characterized by unique OA, pathophysiological processes in cartilage as well as a clinical phenotype. We advocate that further characterization, confirmation and clinical data integration is a prerequisite to allow for development of treatments towards personalized care with concurrently more effective treatment response.

Key words: osteoarthritis, cluster analyses, subtypes, RNA sequencing

Rheumatology key messages

- Osteoarthritis subtypes have been identified however poorly characterized.
- Whole-transcriptome and clinical data integration characterized the existence of two robust OA patient subgroups.
- This study contributes to development of both generic and more personalized OA treatment strategies.

¹Department of Biomedical Data Sciences, Section Molecular Epidemiology, Leiden University Medical Center, Leiden, ²Delft Bioinformatics Lab, Delft University of Technology, Delft, ³Leiden Computational Biology Center, ⁴Sequence Analysis Support Core, Leiden University Medical Center, Leiden, The Netherlands, ⁵Skeletal Research Group, Institute of Genetic Medicine, Newcastle University, Central Parkway, Newcastle upon Tyne, UK and

⁶Department Orthopaedics, Leiden University Medical Center, Leiden, The Netherlands

Submitted 6 December 2019; accepted 4 June 2020

Correspondence to: Ingrid Meulenbelt, Department of Biomedical Data Sciences, Section of Molecular Epidemiology, Leiden University Medical Center, LUMC Post-Zone S-05-P, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: i.meulenbelt@lumc.nl

Introduction

OA is the most common degenerative joint disorder affecting over 40% of people >65 years of age [1]. OA is the result of combinatory risk factors, such as genetics, obesity and older age, and mainly affecting the diarthrodial joints (hands, knees and hips). Although several non-drug therapies are available, there is, as of yet, no effective disease-modifying OA treatment [2]. It is generally accepted that lack of insight into diverse underlying OA processes has contributed to this tempered advancement [3]. To identify OA subtypes, cluster analyses have been performed on clinical data [4, 5] radiographic scores or regional quantitative MRI measures of cartilage [6], which indeed discriminated distinct OA phenotypes. Nonetheless, such phenotypes do not necessarily report on the ongoing disease processes in the joint tissues, hence the lack of information on potential targeted treatments.

To discriminate diverse OA pathophysiological processes in cartilage, Soul *et al.* [7] recently performed a non-negative matrix factorization on RNA sequencing data (RNA-seq) of articular cartilage. Two major subgroups of knee OA patients were identified [7]. These analyses, however, focused on preserved knee OA cartilage only and did not integrate molecular subtypes with clinical data.

In the present study, we used whole-transcriptome RNA-seq data to identify robust OA subgroups, both for knee and for hip OA. Moreover, to identify cluster-specific phenotypes we explored differences in radiographic OA features, joint space narrowing and osteophytosis. Pairwise analysis between preserved and lesioned OA on each cluster highlighted involvement of cluster-specific OA pathways at the molecular level. Together, this study could contribute to the development of both improved generic and more personalized treatment strategies.

Methods

Samples

This study includes a total of $n=66$ primary OA patients (41 knees and 25 hips), who underwent a

joint replacement surgery, from which macroscopically unaffected (preserved $n=56$) and lesioned ($n=45$) OA articular cartilage were collected (RAAK study) [8] (Table 1). Ethical approval for the RAAK study was obtained from the medical ethics committee of the Leiden University medical Center (P08.239) and informed consent was obtained from all participants.

Clinical data

Pre-operative BMI, age, sex and plain radiographs of the relevant hip or knee were present for $n=36$ RAAK subjects included in the RNA-seq and $n=22$ RAAK subjects for which expression from microarray data were available [8]. Radiographs scores (Kellgren and Lawrence, osteophytes and joint space narrowing (JSN)), were performed by two experienced readers (J.M., K.H.) to determine OA characteristics prior and independent of cluster analysis. More details are described in [Supplementary Materials](#), available at *Rheumatology* online.

RNA-seq

Total RNA from cartilage was isolated using Qiagen RNeasy Mini Kit (Qiagen, GmbH, Hilden, Germany). Paired-end 2×100 bp RNA sequencing (Illumina TruSeq RNA Library Prep Kit, Illumina HiSeq2000 and Illumina HiSeq4000) was performed. Strand-specific RNA-seq libraries were generated, which yielded a mean of 20 million reads per sample. See [Supplementary Materials](#), available at *Rheumatology* online for detailed description for alignment, mapping and normalization. Quality control (QC) was performed as previously described [9]. In short, after sequencing QC, principal component analysis (PCA) was applied to remove outliers followed by batch effect correction (details in [Supplementary Materials](#), available at *Rheumatology* online).

TABLE 1 Baseline characteristics of RAAK samples with OA phenotypes included in the cluster analyses

	Total ($n = 36$)	Cluster A ($n = 26$)	Cluster B ($n = 10$)	P-value ^a
Age (s.d.)	69.7 (7.8)	69.7 (8.0)	69.7 (7.7)	0.534 ^a
Females	28 (78)	19 (73)	9 (90)	0.492 ^a
BMI (s.d.)	28.2 (2.9)	28.2 (2.5)	28.2 (4.0)	0.518 ^a
Knee joints	25 (69)	20 (77)	5 (50)	0.059 ^a
KL score (s.d.)	2.7 (0.6)	2.7 (0.7)	2.7 (0.5)	0.720 ^a
OP score (s.d.) ^c	2.7 (2.1)	2.7 (2.2)	2.6 (1.7)	0.931 ^b
JSN score (s.d.) ^c	4.6 (1.2)	4.5 (1.2)	5.0 (1.1)	0.042 ^b

^aP-value by generalized estimation equation (GEE) with cluster-type as dependent variable (Cluster A as reference) and age, sex and joint-type as covariates. ^bP-value by GEE adjusted for age, sex and KL score as covariates. ^cThe OP score or JSN score is defined as the sum of osteophyte grades (0–3) or JSN grades (0–3), respectively determined at the lateral and medial compartments of the tibio-femoral knee joint or at the inferior and superior compartments of the acetabular-femoral hip joint. JSN: joint space narrowing; OP: osteophyte; KL: Kellgren and Lawrence score.

Cluster analysis

To expose subtypes and avoid heterogeneity, we used the preserved cartilage for unsupervised hierarchical clustering. To minimize features (genes), we used a coefficient of variation score [10]. The optimal number of clustering was identified using two approaches: Dynamic Tree Cut [11] and Silhouette width score [12]. To compare similarity between clusters we used the Rand Index, where values ≥ 0.5 were considered significant [13].

Statistical analyses

Differential expression analysis was performed in two ways: between the different clusters; and between pairs of preserved and lesioned cartilage on each cluster separately. The DESeq2 v1.24 R package [14] was used for normalization and statistical framework. A general linear model assuming negative binomial distribution was applied and age, joint type and gender were used as covariates. For the paired analysis between lesioned and preserved cartilage, we used the paired Wald-test. Genes with False Discovery Rate (FDR) < 0.05 were considered significant.

To allow further associations based on OA phenotypes with larger sample size, we integrated microarray data ($n = 22$) (Illumina HumanHT-12 v3 microarrays) with RNA-seq datasets ($n = 36$) from preserved and lesioned articular cartilage. A-Z normalization was applied in both data sets, which were further merged to create a unique gene expression dataset with 58 samples with both OA phenotypes, OP score and JSN score (Supplementary Materials, available at *Rheumatology* online).

Protein-protein interactions and pathway enrichment analysis

Protein-protein interactions (PPI) were performed with STRING v11.0 [15] using the default confidence score > 0.4 as a cut-off criterion to evaluate the PPI information. We used four interaction sources: text mining; experiments; curated databases; and co-expression. Moreover, pathway enrichment analysis was performed using Gene Ontology (GO) for biological process and molecular function in all imputed genes with interactions on the PPI network. Pathways with FDR < 0.05 were considered significant.

Results

To identify subgroups of OA patients, we integrated whole-transcriptome clustering analysis with clinical data in a step-wise approach (Fig. 1). Hereto RNA-seq dataset from OA articular cartilage samples (56 preserved and 45 lesioned, Supplementary Table S1, available at *Rheumatology* online) was used. To expose subtypes and avoid heterogeneity, we applied unsupervised hierarchical clustering analysis on OA preserved cartilage transcriptome ($n = 56$). In order to optimize

discriminative power of the RNA-seq data in the cluster analysis, we first determined the CV of the expressed genes and ranked according to highest degree of variation. Subsequently, by comparing the distribution and cluster performance of OA subgroups using different sets of highest ranked genes (Supplementary Fig. S1, available at *Rheumatology* online), we proceed clustering analyses with the top 1000 genes (Supplementary Table S2, available at *Rheumatology* online).

Unsupervised hierarchical clustering of cartilage samples


Hierarchical clustering analyses of $n = 56$ preserved cartilage samples (Fig. 1A) was applied and both the dynamic tree cut and the silhouette width score methods identified two subgroups of respectively, $n = 41$ (cluster A) and $n = 15$ (cluster B) OA patients (Fig. 2A). To verify whether our identified clusters were robust to clustering method, we applied the non-negative matrix factorization method adapted from Soul *et al.* [7] to the RAAK study dataset (Supplementary Materials, available at *Rheumatology* online). We identified significant comparable clusters in both methods (Rand Index = 0.50).

Differential expression analysis between cluster A and cluster B

To investigate whether the preserved cartilage in cluster A or cluster B had a specific transcriptomic profile (Fig. 1B), we performed differential expression analyses between cluster A and cluster B with cluster A as reference (DE-AB genes). We identified 2967 DE-AB genes with FDR < 0.05 (Fig. 2B, Supplementary Table S3, available at *Rheumatology* online). As shown in Fig. 2B, the most significant DE-AB genes were *STAB1*, encoding Stabilin-1 (FC = 5.8, FDR = 2.7×10^{-28}) and *ACVRL1* encoding Activin A Receptor Like Type 1 (FC = 19, FDR = 1.7×10^{-27}).

Notably, 66% of DE-AB genes were significantly higher expressed in cluster B relative to cluster A. The DE-AB genes in cluster B relative to cluster A with FC > 5 were enriched for genes involved in immune system process (GO: 0002376, 193 genes, FDR = 6.82×10^{-36}) and cell surface receptor signalling pathway (GO: 0007166, FDR = 1.49×10^{-31} , Fig. 4B, Supplementary Table S4, available at *Rheumatology* online). Notable is the presence of several chemokine genes that were extremely highly upregulated in cluster B relative to cluster A, such as *CCL18* encoding chemokine (C-C motif) ligand 18 (FC = 64, FDR = 9.5×10^{-13}), *CXCL1* encoding chemokine (C-X-C motif) ligand 1 (FC = 21, FDR = 1.1×10^{-10}) and *CXCL5* encoding chemokine (C-X-C motif) ligand 5 (FC = 38, FDR = 9.3×10^{-6} , see also Fig. 3).

Conversely, the most significantly upregulated DE-AB genes in cluster A relative to cluster B were *DCN* encoding decorin (FC = 2.1, FDR = 4.4×10^{-13}), *NUDT16P1* encoding nudix hydrolase 16 pseudogene 1 (FC = 2.1, FDR = 7.3×10^{-13}), *NDNF* encoding neuron derived neurotrophic factor (FC = 4.0, FDR = 1.1×10^{-12}), and *THRB* encoding thyroid receptor beta (FC = 2.3,

Fig. 1 Step-wise approach integrating whole-transcriptome clustering analysis with clinical data

(A) Unsupervised hierarchical clustering of the OA preserved cartilage. **(B)** Differential expression analysis between cluster A and B. **(C)** PPI and pathway enrichment analysis with differentially expressed genes unique for each cluster. **(D)** Integration with clinical data.

FDR = 3.6×10^{-12}). The DE-AB genes in cluster A relative to cluster B with FC >2 in cluster A were enriched for genes involved in extracellular matrix (GO: 0031012, FDR = 1.4×10^{-3}) and integral component of membrane (GO: 0016021, FDR = 1.4×10^{-3} , Fig. 4A, Supplementary Table S5, available at *Rheumatology* online).

Differential expression (DE) analysis between preserved and lesioned OA cartilage stratified by cluster

To explore the ongoing pathophysiological process in cluster A and cluster B, we performed pairwise DE analyses between preserved and lesioned OA cartilage stratified by cluster (Fig. 1C). These analyses showed $n = 3201$ significantly DE genes for cluster A (DE-OA-A; Supplementary Fig. S2A and Table S6, available at *Rheumatology* online), and $n = 271$ DE genes for cluster B (DE-OA-B; Supplementary Fig. S2B and Table S7, available at *Rheumatology* online). Of these genes, $n = 172$ were overlapping in both clusters (Supplementary Fig. S2C and Table S8, available at *Rheumatology* online).

To explore the biological pathways of these $n = 172$ overlapping DE genes, we analysed their protein–protein interactions (PPI) using STRING. PPI enrichment showed significantly more interactions between these genes than expected ($P < 1.0 \times 10^{-16}$; Supplementary Fig. S3, available at *Rheumatology* online), with biologically relevant

interplay of genes within GO biological processes such as regulation of response to stimulus (GO: 0018583, FDR = 4.9×10^{-5}), tissue development (GO: 0009888, FDR = 1.6×10^{-4}), and the extracellular region (GO: 0005576, FDR = 9.5×10^{-12}). Moreover, the genes represented in these pathways were previously and consistently reported in OA, such as *IL11*, *FRZB*, *TNFRSF11B*, *NGF*, *WNT16* (Supplementary Table S9, Supplementary Fig. S3, available at *Rheumatology* online).

Cluster A specific differentially expressed genes with OA pathophysiology (DE-OA-A)

To investigate whether we were able to identify the exclusive pathway in the ongoing pathophysiological process in cluster A patients, we selected for DE-OA-A genes not present among the DE-OA-B genes nor among our previous published DE genes of the overall RNA-seq RAAK dataset (Supplementary Fig. S2C, available at *Rheumatology* online). This prioritization led to $n = 1114$ exclusive DE-OA-A genes (Fig. 1C, Supplementary Table S10, available at *Rheumatology* online).

PPI enrichment analyses of exclusive DE-OA-A genes that are downregulated in lesioned as compared with preserved cartilage ($n = 478$, $P < 4.5 \times 10^{-8}$, Supplementary Fig. S4, available at *Rheumatology* online) identified 13 FDR significant GO biological terms and eight GO molecular function terms (Supplementary

Table S11, available at *Rheumatology* online). Of note was enrichment of genes in the chondrocyte hypertrophy pathway (GO-BP: 0003415, FDR = 4.9×10^{-2}) characterized by down regulation of *SOX9*, *RARG* and *TGFBRP2* and the ion-binding pathway (GO-MF: 0043167; FDR = 2.4×10^{-2}) characterized by genes such as *ACACB*, *COL10A1* (in **Supplementary Table S11**, available at *Rheumatology* online).

Conversely, PPI enrichment analyses of exclusive DE-OA-A genes that are upregulated in lesioned as compared with preserved cartilage showed $n = 636$ highly significantly connected genes ($P < 1.0 \times 10^{-16}$, **Supplementary Fig. S5**, available at *Rheumatology* online) in 165 significant GO biological processes such as nucleotide metabolic processes (GO: 0009117, FDR = 1.2×10^{-7}) or cellular component organization – biogenesis (GO: 0071840, FDR = 5.1×10^{-7} , **Supplementary Table S12**, available at *Rheumatology* online).

Cluster B specific differentially expressed genes with OA pathophysiology (DE-OA-B)

Similarly to cluster A, we selected for DE-OA-B genes not present among the DE-OA-A genes nor among our previously published DE genes of the overall RNA-seq RAAK dataset (**Supplementary Fig. S2C**, available at *Rheumatology* online) and identified $n = 72$ exclusive DE-OA-B genes (**Fig. 1C**, **Supplementary Table S13**, available at *Rheumatology* online).

PPI enrichment analyses of exclusive DE-OA-B genes that are downregulated in lesioned as compared with preserved cartilage ($n = 57$) showed highly significant connected genes ($P < 4.5 \times 10^{-8}$) and highlighted 234 FDR significant GO biological terms (**Supplementary Table S14** and **Fig. S6**, available at *Rheumatology* online) particularly involved in biological immune system process (e.g. GO: 0043567, FDR = 6.1×10^{-3}), among others characterized by downregulation of genes such as *HLA-DRB5* and *HLA-DPA1*. Additionally, notable among the downregulated DE-OA-B genes were genes enriched in the molecular function of chemokine activity (GO: 008009, FDR = 2.7×10^{-6}), characterized by, among others, decreased expression of *CCL2*, *CCL3*, *CCL4* and *CCL4-L1* (**Supplementary Table S14**, available at *Rheumatology* online). As shown in **Fig. 3**, these genes were also among the DE-AB genes significantly upregulated in the preserved OA cartilage in cluster B patients relative to cluster A patients.

Conversely, PPI enrichment on exclusive DE-OA-B genes that were upregulated in lesioned compared with preserved OA cartilage ($n = 15$) showed eight genes highly significant connected genes ($P < 3.2 \times 10^{-5}$, **Supplementary Fig. S7**, available at *Rheumatology* online) with enrichment of genes in insulin-like growth factor receptor signalling (GO: 0043567, FDR = 1.0×10^{-3}), characterized by upregulation of *IGFBP6*, *IGFBP5* and *BMP2* (**Supplementary Table S15**, available at *Rheumatology* online). Another notable upregulated DE-OA-B was *DRGX*, encoding the dorsal root ganglia homeobox transcription factor. *DRGX* was highly upregulated in lesioned compared with preserved

cartilage in cluster-B (FC = 30, FDR = 4.0×10^{-4}) and is required for the formation of correct projections from nociceptive sensory neurons to the dorsal horn of the spinal cord and normal perception of pain [16].

Characterization of the OA phenotype in cluster A and cluster B patients

To investigate whether patients in cluster A or cluster B could be characterized by specific radiographic OA features (**Fig. 1D**), pre-operative radiographs were scored for Kellgren and Lawrence scoring (KL score), osteophytes (OPs) and joint space narrowing (JSN). OA phenotypes were available in $n = 36$ out of $n = 56$ samples. As shown in **Table 1**, covariates age, sex and BMI were not significantly different between arthroplasty patients of cluster B relative to cluster A. However, relative to cluster A, we observed more prominent JSN ($P = 4.0 \times 10^{-2}$) in cluster B patients.

To verify our findings, we integrated mRNA expression levels from a previously published microarray mRNA dataset of $n = 22$ preserved and lesioned cartilage of the RAAK study [8] for which we had also assessed OA phenotypes. Upon merging and normalizing mRNA levels of DE genes of the microarray and RNA-seq (**Supplementary methods**, available at *Rheumatology* online), a dataset of 29 DE-AB gene levels in $n = 58$ patients was established. As shown in **Table 2**, the majority of the tested DE-AB genes showed significant association between the mRNA expression levels in preserved cartilage and the OA phenotype JSN such as, for example, *STAB1* with OR = 1.22 (95% CI 1.01, 1.47, $P = 0.0350$). Among these DE-AB genes was also the *NR2F2* showing a highly significant association to higher JSN scores (OR = 1.48, 95%CI 1.26, 1.75, $P = 2 \times 10^{-6}$) in addition to significantly lower OP scores (OR = 0.88, 95%CI 0.81, 0.95, $P = 1.1 \times 10^{-3}$) in cluster B patients relative to cluster A. Moreover, the effect of *NR2F2* gene was similar when stratifying for OA status (preserved or lesioned OA cartilage) or for mRNA quantification method (microarray or RNA-seq).

Discussion

By applying hierarchical clustering on transcriptomic RNA-seq dataset of cartilage, two robust OA patient subgroups (A and B) were recognized. The preserved cartilage in cluster A patients, relative to cluster B (DE-AB genes), was enriched for cartilage related pathways, such as extracellular matrix. With respect to preserved cartilage of cluster B, relative to cluster A, we observed pronounced upregulation of genes involved in chemokine activity pathways (**Supplementary Table S3**, available at *Rheumatology* online). Nevertheless, upon investigating the OA pathophysiology in cluster B patients (DE-OA-B genes), the chemokine genes were significantly down regulated with OA (**Fig. 3**). In parallel, the pathophysiological process in cluster A patients (DE-OA-A genes) between preserved and lesioned

TABLE 2 Associations of mRNA expression level of DE cluster A and cluster B genes with OA phenotypes

Gene	JSN score ^b		OP score ^b	
	OR (95% CI)	P-value ^a	OR (95% CI)	P-value ^a
<i>NR2F2</i>	1.48 (1.26, 1.75)	0.000002	0.88 (0.81, 0.95)	0.0011
<i>MAP4K4</i>	1.37 (1.13, 1.65)	0.0012	1.00 (0.91, 1.1)	0.9919
<i>TPST2</i>	1.30 (1.07, 1.57)	0.0076	0.97 (0.89, 1.06)	0.4699
<i>HCLS1</i>	1.30 (1.05, 1.6)	0.0155	0.92 (0.83, 1.01)	0.0641
<i>FCER1G</i>	1.25 (1.03, 1.53)	0.0276	0.91 (0.83, 1.01)	0.0768
<i>STAB1</i>	1.22 (1.01, 1.47)	0.0350	0.92 (0.83, 1.02)	0.1259
<i>FLRT2</i>	1.20 (1.01, 1.43)	0.0419	0.91 (0.83, 1)	0.0577
<i>CD248</i>	1.24 (1.01, 1.53)	0.0446	0.93 (0.85, 1.02)	0.1043
<i>FYN</i>	1.19 (0.98, 1.44)	0.0722	0.95 (0.86, 1.05)	0.3319
<i>TMEM51</i>	1.22 (0.98, 1.52)	0.0729	0.92 (0.83, 1.02)	0.1133
<i>EXT1</i>	1.21 (0.98, 1.5)	0.0757	1.00 (0.90, 1.11)	0.9798
<i>RALA</i>	1.20 (0.98, 1.47)	0.0774	0.93 (0.85, 1.01)	0.0675
<i>VWF</i>	1.22 (0.97, 1.54)	0.0934	0.94 (0.86, 1.03)	0.1949
<i>CXCL12</i>	1.18 (0.97, 1.44)	0.1059	0.94 (0.85, 1.05)	0.2683
<i>CTSH</i>	1.15 (0.94, 1.41)	0.1625	0.91 (0.82, 1.00)	0.0511
<i>SAMHD1</i>	1.14 (0.94, 1.38)	0.1888	1.03 (0.92, 1.16)	0.5804
<i>MMP9</i>	1.15 (0.92, 1.43)	0.2149	0.94 (0.85, 1.03)	0.1728
<i>MMP19</i>	1.07 (0.88, 1.3)	0.4725	1.02 (0.92, 1.14)	0.6726
<i>EMILIN2</i>	1.08 (0.86, 1.36)	0.5190	0.94 (0.85, 1.04)	0.2244
<i>LGALS3BP</i>	1.05 (0.86, 1.28)	0.6448	1.02 (0.92, 1.13)	0.7416
<i>PTPN6</i>	0.96 (0.78, 1.18)	0.6890	1.00 (0.90, 1.12)	0.9332
<i>PECAM1</i>	1.03 (0.85, 1.26)	0.7499	1.00 (0.91, 1.11)	0.9475
<i>GIMAP7</i>	1.03 (0.84, 1.26)	0.7564	1.02 (0.93, 1.13)	0.6765
<i>STK17B</i>	1.03 (0.84, 1.25)	0.7901	1.01 (0.91, 1.12)	0.8208
<i>FLT4</i>	1.03 (0.84, 1.26)	0.8112	1.02 (0.93, 1.13)	0.6464


^aP-value by generalized estimation equation (GEE) with mRNA expression level in preserved cartilage as dependent variable and age, sex, KL score and joint type as covariates. ^bThe OP score or JSN score is defined as the sum of osteophyte grades (0–3) or JSN grades (0–3), respectively determined at the lateral and medial compartments of the tibio-femoral knee joint or at the inferior and superior compartments of the acetabular-femoral hip joint. JSN: joint space narrowing; OP: osteophyte.

cartilage was characterized by lower expression of genes involved in ion binding and higher expression of genes involved in small molecular metabolic processes (Supplementary Tables S11 and S12, available at *Rheumatology* online). Upon integrating radiographic OA data, we showed that among cluster B patients, relative to cluster A, the OA phenotype may be characterized by higher JSN scores and low OP scores or vice versa. This effect was further strengthened and confirmed by compiling our previously generated mRNA datasets (microarray and RNA-seq) of clinically characterized OA patients while using the DE-AB genes in preserved cartilage as a proxy (Table 2). Notably we merged the OP and JSN score of hips and knees, which may not be entirely appropriate given essential differences in these scorings between knee and hip joints. However, prior to the merging OP and JSN sum scores of knee and hip data, we compared the current results to those obtained merging Z scores of OP and JSN of hip and knee, respectively. Because the results appeared almost identical (data not shown) we have provided data of the sum scores as these are easier to interpret.

Among the individual DE-AB genes, we identified *STAB1* as the most significant upregulated gene in preserved cartilage of cluster B patients (FC = 5.8, FDR = 2.7×10^{-28}). *STAB1* encoding Stabilin-1 is a multifunctional type I transmembrane receptor regulating molecule recycling and cell homeostasis by controlling the intracellular trafficking. Ablation of Stabilin-1 in bone *in vivo* has been shown to enhance bone resorbing activity in osteoclasts [17]. Moreover, Stabilin-1 has been shown to suppress *CCL3* excretion thereby preventing excessive collagen deposition and organ fibrosis [18]. It was subsequently concluded that macrophage Stabilin-1 represents a critical defence against oxidative tissue damage. We found that *CCL3* was highly expressed in cluster B relative to cluster A patients while significantly downregulated with OA status (Fig. 3). This could indicate that the expression pattern of *STAB1* and *CCL3* in cluster B patients reflects a successful defence mechanism against the ongoing OA pathophysiological process. This hypothesis, however, needs to be verified by functional studies, preferably in human *in vitro* models of OA.

Previously clustering analysis on RNA-seq of knee cartilage was performed by applying the relatively

Fig. 2 Unsupervised hierarchical clustering of the OA preserved cartilage and volcano plot



(A) Heatmap displaying subgroup A and B. **(B)** Volcano plot. Cluster B ($n = 15$) is presented as the effector and cluster A ($n = 41$) as reference. Blue circles represent genes lower expressed and red circles indicate genes higher expressed in subgroup B relative to subgroup A.

Fig. 3 Boxplots showing expression pattern of chemokine activity genes in group A and group B





Fig. 4 Top 10 most significant enriched pathways on each cluster

(A) Bar plot represents significantly enriched GO terms for biological process for genes upregulated in cluster A. **(B)** Bar plot represents significantly enriched GO terms for biological process with genes upregulated in cluster B.

complicated, non-negative matrix factorization method [7]. Here we showed that the unsupervised hierarchical clustering applied to our data showed significant cluster similarity upon applying the network NFM method (Rand Index > 0.5), suggesting that our clusters were identified independent of clustering method. Moreover, we found considerable overlap (45%) in the significant DE genes marking the two clusters including *STAB1*, *NR2F2* and chemokine genes (*CCL2*, *CCL3*, *CCL4* and *CCL4-L1*) [7]. This overlap indicates a replication of the existence of two OA subtypes in an independent dataset. Replication of the here-identified associated OA pathophysiological processes and phenotypes is still necessary.

The OA phenotype among patients of cluster B was characterized by pronounced JSN scores. In this respect, two exclusive DE-OA-B genes, *DRGX* and *CCL2* (FC = 30, FDR = 4.0×10^{-4} and FC = 0.4, FDR = 6.0×10^{-4} , respectively) are worth mentioning. *DRGX* encoding the dorsal root ganglia homeobox transcription factor is required for normal perception of pain whereas *CCL2/CCR2* signalling is involved in neuropathic pain and neuroinflammation [19, 20]. In view of the severe joint space narrowing in cluster B patients at total joint replacement surgery, it is tempting to speculate that the ability to upregulate *DRGX* and downregulate *CCL2* could be particularly relevant to mitigate pain (sensitization) during OA pathology. In parallel, we showed that the expression levels of the DE-AB gene *NR2F2* are low in cluster B related to cluster A (FC = 0.2, FDR = 4.1×10^{-14}) and could quantitatively mark OA patients with severe JSN and mild OPs or vice versa. *NR2F2* encodes a transcription factor activated by ligands such as high concentrations of 9-cis-retinoic acid and all-trans-retinoic acid, but not by dexamethasone, cortisol or progesterone. *NR2F2* is activated in response to oxidative stress and induces the expression

of its target genes by binding to the antioxidant response element. Oxidative stress has been described as an important factor in OA and its regulation in chondrocytes have been proposed as a potential new target for therapy [21]. The deletion of *Nrf2* in a murine post-traumatic model resulted in increased OA severity, while the use of histone deacetylase inhibitors activates *Nrf2*, repressing IL-1 β -induced *MMP1*, *MMP3* and *MMP13* gene expression in chondrocytes and in mouse joint tissues [22]. Altogether, this supports that the lower levels of *NR2F2* gene in cluster B could lead to a more severe form of OA related JSN, as observed in our study.

Finally, we found two HLA genes among the exclusive DE-OA-B genes; *HLA-DRB5* and *HLA-DPA1*, that were significantly downregulated (FC = 0.3, FDR = 1.5×10^{-2} and FC = 0.3, FDR = 4.5×10^{-4} , respectively). For that matter, *HLA-DRB5* has repeatedly been positively associated with RA whereas *HLA-DPA1* was recently identified as risk gene in a GWAS on OA phenotypes [23]. In this GWAS it was speculated that the readily available RA drugs could possible function as new candidates to treat OA patients. As these HLA genes are here found to be significantly downregulated in OA lesioned cartilage drug targeting, these genes may likely not have a strong beneficial effect to the ongoing OA pathophysiology. We selected for the exclusive DE-OA-A and DE-OA-B genes (i.e. significantly DE only in either cluster and not significant in the overall dataset) to explore the specific characteristics in the OA pathophysiological process. Nonetheless, due to the relatively large difference in representative patients of cluster A and cluster B, hence, power, we cannot exclude a likely small proportion of false-positive or false-negative selection among these exclusive genes.

Among the most consistently upregulated genes with OA pathophysiology [9] and also reported here, are *IL11* and *FGF18*. Notably, these genes were recently found in

large GWAS on OA, also indicating their causal involvement in the OA pathophysiology [23]. Moreover, they were recognized as being targeted by Food and Drug Administration approved drugs [24]. With respect to *IL11*, the OA risk allele of rs4252548 (missense variant p. Arg112His) acts via lower stability of IL-11, suggesting that the demonstrated upregulation of *IL11* expression with OA pathology is a final, yet failing attempt to respond to the OA disease process. Interestingly, recombinant IL-11 molecules are available as therapeutics of thrombocytopenia in cancer patients [25, 26]. As such, this would make IL11 an attractive potential drug for OA patients. Results of the current study suggest, however, that this may be particularly true for cluster A relative to cluster B patients (FC = 19 vs FC = 60, respectively). Similarly, *FGF18* (fibroblast growth factor 18) was upregulated in lesioned OA cartilage in both clusters (FC = 1.6 in cluster A and FC = 1.9 in cluster B). FGF18 is a member of the FGF family and participates in several processes, including skeletal growth and development regulation of chondrogenesis, osteogenesis, and bone and mineral homeostasis [27]. Furthermore, intra-articular injections of FGF18 into the knee of OA patients have resulted in a dose-dependent reduction of cartilage loss [28]. More recently, recombinant human FGF18 protein (Sprifermin) is tested for its therapeutic potential as disease-modifying OA drug [29, 30]. As the differential expression of *FGF18* showed similar fold change upregulated in lesioned OA cartilage in both clusters, this treatment could affect patients in a similar way.

Taken together, we have here shown the existence of two major OA subtypes independent of joint site. These OA subtypes were characterized by a unique OA, pathophysiological process in cartilage as well as radiographic phenotype. We advocate that further characterization, confirmation, and clinical data integration is a prerequisite to allow for development of treatments towards personalized care with concurrently more effective treatment response.

Acknowledgements

We thank all study participants of the RAAK study. The Leiden University Medical Centre have and is supporting the RAAK study and studies are being performed within the scope of the Medical Delta programs Regenerative Medicine 4D: Generating complex tissues with stem cells and printing technology and Improving Mobility with Technology. All authors have made substantial contributions to the completion of this study: Study concept and design: R.C.A., Y.F.M.R., A.M., M.R., I.M.; data analyses: R.C.A., A.M., Y.F.M.R., H.M., J.S.; acquisition of material and data: R.C.A., W.dH., E.H., E.S., N.L., J.M., K.H., R.G.H.H.N., Y.F.M.R., I.M.; preparation of the manuscript: R.C.A., Y.F.M.R., A.M., M.R., I.M.; critical reviewing and approval of the manuscript: all authors.

Funding: This work was supported by Foundation for Research in Rheumatology (FOREUM), Dutch Arthritis

Society (DAS-10-1-402), BBMRI-NL complementation project (CP2013-83), Ana Fonds (O2015-27) and the Dutch Scientific Research council NWO/ZonMW VICI scheme (91816631/528).

Disclosure statement: The authors have declared no conflicts of interest.

Supplementary data

Supplementary data are available at *Rheumatology* online.

References

- 1 GBD 2015 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; 388:1603-58.
- 2 Oo WM, Hunter DJ. Disease modification in osteoarthritis: are we there yet? *Clin Exp Rheumatol* 2019;37(Suppl 120):135-40.
- 3 Karsdal MA, Michaelis M, Ladel C *et al.* Disease-modifying treatments for osteoarthritis (DMOADs) of the knee and hip: lessons learned from failures and opportunities for the future. *Osteoarthritis Cartilage* 2016; 24:2013-21.
- 4 Knoop J, van der Leeden M, Thorstensson CA *et al.* Identification of phenotypes with different clinical outcomes in knee osteoarthritis: data from the Osteoarthritis Initiative. *Arthritis Care Res* 2011;63: 1535-42.
- 5 Castano-Betancourt MC, Rivadeneira F, Bierma-Zeinstra S *et al.* Bone parameters across different types of hip osteoarthritis and their relationship to osteoporotic fracture risk. *Arthritis Rheum* 2013;65:693-700.
- 6 Waarsing JH, Bierma-Zeinstra SM, Weinans H. Distinct subtypes of knee osteoarthritis: data from the osteoarthritis initiative. *Rheumatology* 2015;54:1650-8.
- 7 Soul J, Dunn SL, Anand S *et al.* Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage. *Ann Rheum Dis* 2018;77:423.
- 8 Ramos YF, den Hollander W, Bovee JV *et al.* Genes involved in the osteoarthritis process identified through genome wide expression analysis in articular cartilage; the RAAK study. *PLoS One* 2014;9:e103056.
- 9 Coutinho de Almeida R, Ramos YFM, Mahfouz A *et al.* RNA sequencing data integration reveals an miRNA interactome of osteoarthritis cartilage. *Ann Rheum Dis* 2019;78:270-277.
- 10 Li W, Fan M, Xiong M. SamCluster: an integrated scheme for automatic discovery of sample classes using gene expression profile. *Bioinformatics* 2003;19:811-7.
- 11 Langfelder P, Zhang B, Horvath S. Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. *Bioinformatics* 2008;24:719-20.

- 12 Charrad M, Ghazzali N, Boiteau V, Niknafs A. NbClust: an R package for determining the relevant number of clusters in a data set. *Journal of Statistical Software* 2014;61:36.
- 13 Rand WM. Objective criteria for the evaluation of clustering methods. *J Am Stat Assoc* 1971;66:846–850.
- 14 Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 2014;15:550.
- 15 Szklarczyk D, Gable AL, Lyon D *et al*. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. *Nucleic Acids Res* 2019;47:D607–d613.
- 16 Regadas I, Matos MR, Monteiro FA *et al*. Several cis-regulatory elements control mRNA stability, translation efficiency, and expression pattern of Prrxl1 (paired related homeobox protein-like 1). *J Biol Chem* 2013;288:36285–301.
- 17 Kim SY, Lee EH, Park SY *et al*. Ablation of stabilin-1 enhances bone-resorbing activity in osteoclasts in vitro. *Calcif Tissue Int* 2019;105:205–14.
- 18 Rantakari P, Patten DA, Valtonen J *et al*. Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury. *Proc Natl Acad Sci USA* 2016;113:9298–9303.
- 19 Ramesh G. Novel therapeutic targets in neuroinflammation and neuropathic pain. *Inflamm Cell Signal* 2014;1:e111.
- 20 Miller RE, Tran PB, Das R *et al*. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. *Proc Natl Acad Sci USA* 2012;109:20602–7.
- 21 Poulet B, Beier F. Targeting oxidative stress to reduce osteoarthritis. *Arthritis Res Ther* 2016;18:32.
- 22 Cai D, Yin S, Yang J, Jiang Q, Cao W. Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis. *Arthritis Res Ther* 2015;17:269.
- 23 Styrkarsdottir U, Lund SH, Thorleifsson G *et al*. Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, IL11, COL11A1 and 13 more new loci associated with osteoarthritis. *Nat Genet* 2018;50:1681–1687.
- 24 Tachmazidou I, Hatzikotoulas K, Southam L *et al*. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. *Nat Genet* 2019;51:230–236.
- 25 Kurzrock R. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. *Oncology* 2000;14(9 Suppl 8):9–11.
- 26 Tsimberidou AM, Giles FJ, Khouri I *et al*. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. *Ann Oncol* 2005;16:139–45.
- 27 Liu Z, Lavine KJ, Hung IH, Ornitz DM. FGF18 is required for early chondrocyte proliferation, hypertrophy and vascular invasion of the growth plate. *Dev Biol* 2007;302:80–91.
- 28 Lohmander LS, Hellot S, Dreher D *et al*. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheumatol* 2014;66:1820–31.
- 29 Gigout A, Guehring H, Froemel D *et al*. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix. *Osteoarthritis Cartilage* 2017;25:1858–1867.
- 30 Reker D, Kjelgaard-Petersen CF, Siebuhr AS *et al*. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo. *J Transl Med* 2017;15:250.